Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Epothilone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Epothilone. Displaying page 1 of 1.
    EudraCT Number: 2005-005877-31 Sponsor Protocol Number: ZK219477-01 Start Date*: 2006-03-27
    Sponsor Name:ISTITUTO NEUROLOGICO CARLO BESTA
    Full Title: Phase II study Systemic treatment with ZK219477 EPOTHILONE in recurrent Glioblastoma patients
    Medical condition: Recurrent Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10018336 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007167-16 Sponsor Protocol Number: CA163-196 Start Date*: 2009-09-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who H...
    Medical condition: Advanced, recurrent or metastatic endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014745 Endometrial carcinoma metastatic LLT
    9.1 10014747 Endometrial carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed) IT (Prematurely Ended) ES (Temporarily Halted) FR (Completed) SE (Completed) GR (Completed) DK (Completed) HU (Completed) FI (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004252-40 Sponsor Protocol Number: CEPO906A2209 Start Date*: 2005-09-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, Phase I/II, dose escalating study evaluating the safety and efficacy of EPO906, q3w, in patients with non-small cell lung cancer
    Medical condition: Non-small cell lung cancer (NSCLC) - patients with inoperable stage IIIb or IV NSCLC have a very poor prognosis, with overall survival of 4-8 months.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004913-14 Sponsor Protocol Number: CEPO906A2203 Start Date*: 2005-08-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label Phase I/II dose escalation study evaluating the safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer
    Medical condition: Approximately 75% of women with ovarian cancer present advanced disease. Survival is highly dependent on the stage of disease at the initiation of treatment. Favorable prognostic factors include y...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001432-31 Sponsor Protocol Number: CA190001 Start Date*: 2008-04-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects with Advanced Cancer. Revised Protocol 02, incorporating Protocol Amend...
    Medical condition: Advanced Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001433-34 Sponsor Protocol Number: CA190002 Start Date*: 2008-03-14
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects with Advanced Cancer. Revised Protocol 04, incorporating Protocol Amendme...
    Medical condition: Advanced cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000977-39 Sponsor Protocol Number: CA163-163 Start Date*: 2008-11-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects With Advanced Non-Small Cell Lung Cancer Revised Protocol 02 incorporating Amendment 03 (vers...
    Medical condition: Advanced Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006073-24 Sponsor Protocol Number: CCR2983 Start Date*: 2008-05-22
    Sponsor Name:Royal Marsden Hospital
    Full Title: CINATRA: Chromosomal Instability and Anti-Tubulin Response Assessment: A Phase II Study of Epothilone B in Metastatic Colon Carcinoma in patients with Microsatellite Instability or Chromosomal Inst...
    Medical condition: Metastatic or locally recurrent colorectal cancer in genetically unselected patients, followed by recruitment of patients selected for microsatellite positive tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010035 Colorectal cancer stage IV LLT
    9.1 10010030 Colorectal cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005209-23 Sponsor Protocol Number: CA163139 Start Date*: 2008-03-21
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects with Triple Negative (ER, PR, Her2 negative) Locally Advanced non-resectable and/...
    Medical condition: BREAST CANCER, FIRST LINE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Gender: Female
    Trial protocol: FR (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-003047-24 Sponsor Protocol Number: CA163-100 Start Date*: 2007-05-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women with Early Stage Breast Cancer Not Overexpressin...
    Medical condition: BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Completed) IT (Completed) GB (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-005181-20 Sponsor Protocol Number: CEPO906A2303 Start Date*: 2006-05-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/r...
    Medical condition: Approximately 75% of women with ovarian cancer present advanced disease. Survival is highly dependent on the stage of disease at the initiation of treatment. Favorable prognostic factors include yo...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) FI (Completed) DK (Completed) HU (Completed) GR (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001822-23 Sponsor Protocol Number: CEPO906A2229 Start Date*: 2006-07-29
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A Randomized Multicenter Phase II Trial of Patupilone (EPO906) plus Prednisone versus Docetaxel (Taxotere) plus Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer
    Medical condition: Cancer of the prostate is the most commonly diagnosed neoplasm in men in the United States after skin cancer. In 2002, over 189,000 new cases were diagnosed in United States representing 30% of all...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000721-21 Sponsor Protocol Number: CA163-140 Start Date*: 2007-09-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized Phase II study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects with Her2+ Locally Advanced and/or Metastatic Breast Cancer.
    Medical condition: Female Subjects with Her2+ Locally Advanced and/or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) GR (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001921-25 Sponsor Protocol Number: CA163115 Start Date*: 2006-12-19
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as first Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
    Medical condition: Locally Recurrent or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001659-37 Sponsor Protocol Number: 26061 Start Date*: 2007-06-25
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Phase II Study of ZK 219477 in patients with recurrent glioblastoma
    Medical condition: Phase II study of ZK 219477 in patients with recurrent glioblastoma.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018336 Glioblastoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006494-24 Sponsor Protocol Number: PACS 08/0610 Start Date*: 2007-06-06
    Sponsor Name:Fédérationa Nationale des Centres de Lutte Contre le Cancer
    Full Title: Randomized, open label, multicentric phase III trial evaluating the benefit of a sequential regimen associating FEC100 and Ixabepilone in adjuvant treatment of non metastatic, poor prognosis breas...
    Medical condition: non-metastatic operable breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 09:44:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA